Mimouni Michael, Trinh Tanya, Sorkin Nir, Cohen Eyal, Santaella Gisella, Rootman David S, Slomovic Allan R, Chan Clara C
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada.
Department of Ophthalmology, Tel Aviv Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Eur J Ophthalmol. 2021 Apr 22:11206721211011354. doi: 10.1177/11206721211011354.
To report outcomes of a sutureless dehydrated amniotic membrane for persistent epithelial defects (PED).
This retrospective study included consecutive patients with a PED (⩾14 days) treated with a sutureless dehydrated amniotic membrane and bandage contact lens (BCL). Included were patients with an epithelial defect that did not respond to treatment with a BCL. Excluded were patients with a follow-up time of less than 3 months.
Nine eyes of eight patients with a mean age of 54.6 ± 10.9 years (range 38-73 years) were included in this study. The main etiology of the PED was limbal stem cell deficiency ( = 5/9) due to Stevens-Johnson Syndrome ( = 2/5), glaucoma procedures ( = 1/5), graft-versus-host disease ( = 1/5) and severe allergic reaction ( = 1/5). Additional etiologies included neurotrophic cornea ( = 2/9), post keratoplasty and severe dry eye disease ( = 2/9). Time from PED presentation to amnion treatment was 65.9 ± 60.6 days (range 15-189 days) with the area of the PED being 11.0 ± 12.2 mm (range 1.0-36.0 mm). The amnion was absorbed within 2 weeks in 100% of the cases. Following insertion of the amnion, resolution of the PED was achieved in 8/9 eyes (89%) without the need for additional interventions within 17.8 ± 9.6 days (range 7-35 days). LogMAR BCVA improved from 0.94 ± 0.88 to 0.37 ± 0.25 ( = 0.036) with no complications or recurrences recorded.
Sutureless dehydrated amniotic membrane achieved resolution of PEDs secondary to various etiologies in 89% of eyes with a significant improvement in vision demonstrated. Further studies are needed to assess long term safety and effectiveness.
报告使用无缝合脱水羊膜治疗持续性上皮缺损(PED)的结果。
这项回顾性研究纳入了连续的PED患者(病程≥14天),这些患者接受了无缝合脱水羊膜和绷带式隐形眼镜(BCL)治疗。纳入的患者为上皮缺损对BCL治疗无反应者。排除随访时间少于3个月的患者。
本研究纳入了8例患者的9只眼,平均年龄为54.6±10.9岁(范围38 - 73岁)。PED的主要病因是角膜缘干细胞缺乏(5/9),其原因包括史蒂文斯 - 约翰逊综合征(2/5)、青光眼手术(1/5)、移植物抗宿主病(1/5)和严重过敏反应(1/5)。其他病因包括神经营养性角膜病变(2/9)、角膜移植术后和严重干眼疾病(2/9)。从PED出现到羊膜治疗的时间为65.9±60.6天(范围15 - 189天),PED面积为11.0±12.2平方毫米(范围1.0 - 36.0平方毫米)。100%的病例中羊膜在2周内被吸收。植入羊膜后,8/9只眼(89%)的PED得到解决,无需在17.8±9.6天(范围7 - 35天)内进行额外干预。对数最小分辨角视力(LogMAR BCVA)从0.94±0.88提高到0.37±0.25(P = 0.036),未记录到并发症或复发情况。
无缝合脱水羊膜使89%继发于各种病因的PED得到解决,视力有显著改善。需要进一步研究来评估其长期安全性和有效性。